The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

开始日期2024-06-01

申办/合作机构-

NCT06248515 / Recruiting临床2期IIT

A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy.
The main question it aims to answer is:
• What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma?
Participants will:
receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity
have regular blood tests, scans, and examinations to monitor their health.
have blood and a biopsy of their tumor for research purposes.

开始日期2024-04-25

申办/合作机构

Georgetown University Hospital

[+1]

NCT06402708 / Recruiting临床3期IIT

Postoperative Adjuvant Treatment for Thymic Cancer With Completed Resection (Radiotherapy vs Chemoradiotherapy): A Prospective, Multicenter, Open-label, Phase III, Randomized Controlled Trial

The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are:
Does adjuvant chemotherapy decrease disease progression?
Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance?
Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not.
Participants will:
Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF).
Follow up every 3 months in the first two year, and then every 6 months.

开始日期2024-04-09

申办/合作机构

复旦大学

100 项与胸腺癌相关的临床结果

登录后查看更多信息

100 项与胸腺癌相关的转化医学

登录后查看更多信息

0 项与胸腺癌相关的专利（医药）

登录后查看更多信息

1,892

项与胸腺癌相关的文献（医药）

2024-11-01·Indian Journal of Thoracic and Cardiovascular Surgery

Clinical features and prognostic factors in thymoma and thymic carcinoma

Article

作者: Uncu, Dogan ; Kos, Fahriye Tugba ; Civelek, Burak ; Bayram, Doğan ; Bal, Oznur ; Sekmek, Serhat ; Şendur, Mehmet Ali Nahit ; Bardakçı, Murat ; Kayaalp, Mehmet ; Algin, Efnan ; Hafızoğlu, Emre ; Uçar, Gökhan

IntroductionThymic epithelial tumors represent the most common cause of anterior mediastinal masses in adults. Among these tumors, thymomas constitute the majority, whereas thymic carcinomas are less prevalent and associated with a poorer prognosis. This study seeks to investigate the clinical and prognostic factors of these rare entities, thymoma, and thymic carcinomas.Materials and methodsWe conducted a retrospective analysis on a cohort of 60 patients diagnosed with thymoma and thymic carcinoma, who were under follow-up at our clinic between January 1998 and February 2023. The clinical characteristics and prognostic factors of these patients were analyzed separately.ResultsThymomas accounted for 75% of the cases. The median age at diagnosis was 46 years in both patient groups. Masaoka stage 4 was observed in 28.9% of thymoma patients and 66.7% of thymic carcinoma patients. The median overall survival (mOS) for thymoma patients was 261.4 months, while it was 9.23 months for patients with thymic carcinoma. Curative surgery emerged as a prognostic factor significantly influencing overall survival in both thymoma and thymic carcinoma patients.ConclusionOur study highlights the significance of Eastern Cooperative Oncology Group (ECOG) performance status and curative surgery as prognostic factors affecting overall survival in thymoma patients. In thymic carcinoma, only curative surgery was found as a prognostic factor. These findings may enhance patient care and guide personalized treatment strategies. Further investigations and prospective studies are warranted to corroborate and expand upon these results.

2024-11-01·Indian Journal of Thoracic and Cardiovascular Surgery

Thymoma and thymic carcinoma

Article

作者: Jain, Satinder Kumar

2024-10-01·Cancer Epidemiology

The contribution of rural/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000–2020 database

Article

作者: Patel, Vani ; Mompoint, Annsophia ; Daon, Emmanuel ; Cascone, Joseph ; Taylor, Mitchell ; Ituarte, Bianca

OBJECTIVERural-urban healthcare disparities have been demonstrated throughout the United States, particularly in acquiring oncologic care. In this study, we aim to discern the role of rural-urban health disparities in thymic cancer incidence and uncover potential survival disparities.METHODSThe Surveillance, Epidemiology, and End Results (SEER) 17-State database was queried for all cases of thymoma (ICD-O-3/3 codes: 8580-8585) and thymic carcinoma (8586) located in the thymus (primary site code C37.9) diagnosed between 2000 and 2020. Residence was established using SEER Rural-Urban Continuum Codes. Incidence trend modeling for rural versus urban patients was completed using Joinpoint Regression Software. Chi-square, Kaplan-Meier with log-rank testing, and Cox proportional hazards was completed using SPSS, with significance set to p <0.05.RESULTSJoinpoint analysis revealed a significant growth in incidence in the urban population compared to a stagnant incidence among the rural population. Disease specific survival was higher among urban patients on univariate modeling (p = 0.010), and confirmed on multivariate analysis, whereby rural living conferred an adjusted hazard ratio of 1.263 (95 % CI 1.045-1.527; p = 0.016) in comparison to urban patients.CONCLUSIONSThese findings demonstrate differences between thymic cancer incidence and outcomes in patients living in urban versus rural environments and demonstrate an important disparity.

项与胸腺癌相关的新闻（医药）

2024-10-25

·ioncology

ESMO ASIA 2024丨一文了解胸部肿瘤口头报告

点击蓝字关注我们 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia Congress 2024）将于当地时间12月6日~8日在新加坡召开。ESMO ASIA是亚太地区讨论肿瘤学领域重磅突破的领先平台，近日在官方网站正式公布本次大会的摘要题目及作者信息。肿瘤瞭望小编带您先睹为快，一览胸部肿瘤领域入选优选口头报告（Proffered Paper）和微型口头报告（Mini Oral）的临床研究。 1 优选口头报告（Proffered Paper）摘要号：LBA8 英文标题：Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study 中文标题：阿替利珠单抗+卡铂/紫杉醇治疗转移性或复发性胸腺癌的II期临床试验：Marble研究讲者：Tomoyasu Mimori (日本) 摘要号：625O 英文标题：Efficacy and safety of Lucitanib (AL3810) in second or subsequent-line treatment of advanced recurrent or metastatic thymic carcinoma: a randomized, double-blind, placebo-controlled multicenter phase II trial 中文标题：Lucitanib在晚期复发或转移性胸腺癌二线或后续治疗中的疗效和安全性：一项随机、双盲、安慰剂对照的多中心II期试验讲者：方文涛（上海交通大学医学院附属胸科医院）摘要号：LBA5 英文标题：Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of Beamion LUNG-1 中文标题：Zongertinib治疗HER2突变型NSCLC患者：Beamion LUNG-1的最新分析讲者：Noboru Yamamoto (日本) 摘要号：LBA6 英文标题：PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT) 中文标题：PACIFIC-5：针对同步或序贯放化疗（cCRT或sCRT）后未出现进展不可切除III期NSCLC患者进行巩固性度伐利尤单抗治疗的III期研究讲者：吴一龙（广东省人民医院）摘要号：LBA7 英文标题：Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): a pooled analysis of TROPION-Lung01 and TROPION-Lung05 中文标题：Dato-DXd对既往接受过治疗的EGFR突变晚期非小细胞肺癌患者的疗效和安全性：TROPION-Lung01和TROPION-Lung05的汇总分析讲者：Myung-Ju Ahn (韩国) 2 微型口头报告（Mini Oral）摘要号：626MO 英文标题：Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase 2 DeLLphi-301 study 中文标题：Tarlatamab治疗既往接受过治疗的小细胞肺癌：II期DeLLphi-301研究中亚洲地区患者的亚组分析讲者：Hiroaki Akamatsu (日本) 摘要号：627MO 英文标题：POD1UM-304: Phase 3 Study of Retifanlimab Plus Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Therapy For Nonsquamous or Squamous Metastatic Non–Small Cell Lung Cancer (mNSCLC) 中文标题：POD1UM-304：Retifanlimab+铂类化疗作为非鳞或鳞状转移性非小细胞肺癌一线疗法的III期研究讲者：陆舜(上海交通大学医学院附属胸科医院) 摘要号：614MO 英文标题：A Phase Ⅱ Study of Becotatug (JMT101) in Combination with Osimertinib (Osi) in Patients (pts) with classical EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (BOOSTER Study) 中文标题：Becotatug联合奥希替尼治疗经典型EGFR突变非小细胞肺癌患者的Ⅱ期BOOSTER临床研究讲者：张力(中山大学肿瘤防治中心) 摘要号：630MO 英文标题：First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort 中文标题：一线奥希替尼±铂类-培美曲塞化疗治疗EGFR突变晚期非小细胞肺癌：FLAURA2亚洲队列讲者：James Chih-Hsin Yang (中国台湾) 摘要号：628MO 英文标题：Comparing Subcutaneous vs Intravenous Amivantamab with Lazertinib in EGFR-Mutated Advanced NSCLC: Analysis of Asian Patients From PALOMA-3 中文标题：比较皮下注射vs静脉注射Amivantamab联合Lazertinib治疗EGFR突变晚期NSCLC：对PALOMA-3亚洲患者的分析讲者：Se-Hoon Lee (韩国) 摘要号：629MO 英文标题：ALESIA 7-year update: alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC) 中文标题：ALESIA研究7年随访更新：阿来替尼vs克唑替尼在未经治疗的晚期ALK+非小细胞肺癌亚洲患者中的疗效对比讲者：周彩存(上海市东方医院) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床2期临床结果临床3期

2024-10-16

·复星医药

复星医药：药友制药甲磺酸仑伐替尼胶囊获批上市

2024年10月14日，国家药品监督管理局官网显示，药友制药的甲磺酸仑伐替尼胶囊（4mg、10mg）获批上市并视同过评。 2015年在美国首次上市，2018年进入中国。中国市场批准用于：（1）既往未接受过全身系统治疗的不可切除的肝细胞癌患者。（2）进展性、局部晚期或转移性放射性碘难治性分化型甲状腺癌患者。法规市场还批准用于：单药治疗胸腺癌、联合依维莫司二线治疗肾癌、联合帕博利珠单抗一线治疗肾癌和既往经全身治疗的子宫内膜癌患者。另有联合肝动脉化疗栓塞术（TACE）一线治疗肝癌、联合化疗一线治疗食管癌、联合化疗一线治疗胃癌等多项国际多中心3期临床试验正在进行中。仑伐替尼是一种酪氨酸激酶受体（RTK）抑制剂，可抑制血管内皮生长因子（VEGF）受体VEGFR1（FLT1）、VEGFR2（KDR）和VEGFR3（FLT4）的激酶活性，另外还可抑制其它促血管生成和肿瘤发生通路相关的RTK，包括成纤维细胞生长因子（FGF），受体FGFR1、2、3和4，血小板衍生生长因子（PDGF）受体PDGFRα、KIT和RET。一项关键临床（REFLECT试验）中国亚组分析显示，仑伐替尼在中国肝癌患者中表现更优，中位无进展生存期（mPFS）和中位总生存期（mOS）较全球数据更佳。仑伐替尼被CSCO、NCCN等海内外权威指南推荐用于一线治疗肝癌，是中国肝癌系统治疗的临床首选药物之一。甲磺酸仑伐替尼胶囊属医保乙类，已于2022年进入国家带量采购目录（第七批），协议期至2025年11月。目前，中国市场规模超17亿元，市场容量持续高速增长，近4500万粒（以4mg计）。内容来源于网络，如有侵权，请联系删除。

上市批准CSCO会议

2024-10-14

·医药观澜

卫材口服癌症新药「仑伐替尼」新适应症在中国申报上市

10月12日，中国国家药监局药品审评中心（CDE）官网公示，卫材（Eisai）申报的甲磺酸仑伐替尼胶囊新适应症上市申请获得受理，具体适应症尚未公示。仑伐替尼为卫材公司研发的一种口服多激酶抑制剂，此前已经在全球范围内获批多项癌症适应症。公开资料显示，仑伐替尼（lenvatinib）是一种口服多种激酶抑制剂，可以选择性抑制多种激酶的活性，包括血管内皮生长因子受体（VEGFR1、VEGFR2和VEGFR3），以及成纤维细胞生长因子受体（FGFR1、FGFR2、FGFR3和FGFR4），此外还有致病性血管生成、肿瘤生长和癌症进展相关受体酪氨酸激酶，如血小板衍生生长因子受体α（PDGFRα）、KIT和RET。仑伐替尼作为单药，已经在日本、美国、欧洲、中国等国家和地区获批用于一线治疗甲状腺癌和肝细胞癌，在日本也被批准用于治疗胸腺癌。仑伐替尼与依维莫司联合疗法已经在美国、欧洲和亚洲等地被批准用于二线治疗肾细胞癌；与抗PD-1单抗帕博利珠单抗组成的联合疗法已经在多地获批用于一线治疗肾细胞癌、既往经过全身治疗的子宫内膜癌等。根据卫材官网最新管线信息，仑伐替尼还有3项国际多中心（含中国）3期临床研究正在进行中，针对适应症包括：联合经动脉化疗栓塞术（TACE）一线治疗肝细胞癌（LEAP-012研究）；联合化疗一线治疗食管癌（LEAP-014）；联合化疗一线治疗胃癌（LEAP-015）。在今年的美国临床肿瘤学会（ASCO）年会上，研究人员还公布了LEAP-012研究的研究结果，该研究旨在评估评估帕博利珠单抗+仑伐替尼联合TACE与双安慰剂+TACE治疗不可切除的非转移性肝细胞癌（HCC）患者的疗效。研究表明，在中位随访25.6个月后，帕博利珠单抗+仑伐替尼联合TACE在无进展生存方面显示出具有统计学意义和临床意义的改善，与单独使用TACE相比，将疾病进展或死亡风险降低了34%。帕博利珠单抗+仑伐替尼方案的中位无进展生存期为14.6个月，而TACE方案的中位无进展生存期为10.0个月。期待仑伐替尼后续临床研究也顺利进行，早日为更多的患者带来新的治疗选择。参考资料： [1]中国国家药监局药品审评中心（CDE）官网. Retrieved Oct 12，2024, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]卫材官网研发管线. Retrieved Aug 2, 2024, from https://www.eisai.com/innovation/research/pipeline/index.html [3]LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC. Retrieved Sep 16, 2024, from https://ascopost.com/news/september-2024/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free-survival-in-hcc/ 内容来源于网络，如有侵权，请联系删除。